Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone609-275-0500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.19 billion
Profitability
Miscellaneous
Employees4,400
OptionableOptionable
Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions
What is Integra Lifesciences' stock symbol?
Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART."
When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work?
Integra Lifesciences shares split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split.
How were Integra Lifesciences' earnings last quarter?
Integra Lifesciences Holdings Corp (NASDAQ:IART) released its earnings results on Wednesday, October, 31st. The life sciences company reported $0.59 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.59. The life sciences company earned $365.85 million during the quarter, compared to analyst estimates of $367.89 million. Integra Lifesciences had a return on equity of 16.99% and a net margin of 5.49%. The firm's quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.45 EPS. View Integra Lifesciences' Earnings History.
When is Integra Lifesciences' next earnings date?
How can I listen to Integra Lifesciences' earnings call?
Integra Lifesciences will be holding an earnings conference call on Thursday, February 21st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 3343230522.
What price target have analysts set for IART?
13 brokers have issued 12 month price objectives for Integra Lifesciences' stock. Their predictions range from $54.00 to $70.00. On average, they expect Integra Lifesciences' stock price to reach $61.4167 in the next twelve months. This suggests a possible upside of 20.3% from the stock's current price. View Analyst Price Targets for Integra Lifesciences.
What is the consensus analysts' recommendation for Integra Lifesciences?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Integra Lifesciences.
Has Integra Lifesciences been receiving favorable news coverage?
Headlines about IART stock have been trending neutral on Saturday, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Integra Lifesciences earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the life sciences company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Integra Lifesciences' key competitors?
Some companies that are related to Integra Lifesciences include ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Penumbra (PEN), ICU Medical (ICUI), Insulet (PODD), Novocure (NVCR), Globus Medical (GMED), Haemonetics (HAE), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA) and Tandem Diabetes Care (TNDM).
Who are Integra Lifesciences' key executives?
Integra Lifesciences' management team includes the folowing people:
- Mr. Peter J. Arduini, Pres, CEO & Director (Age 54)
- Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 76)
- Mr. Glenn G. Coleman, Corp. VP of International & CFO (Age 51)
- Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 56)
- Mr. Robert T. Davis Jr., Corp. VP and Pres of Orthopedics & Tissue Technologies (Age 60)
Who are Integra Lifesciences' major shareholders?
Integra Lifesciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.90%), Oregon Public Employees Retirement Fund (1.47%), Brown Advisory Inc. (1.19%), Fisher Asset Management LLC (1.11%), Vaughan Nelson Investment Management L.P. (1.03%) and Jennison Associates LLC (1.01%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Donald E Morel Jr, Glenn Coleman, James M Sullivan, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Richard D Gorelick, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences.
Which institutional investors are selling Integra Lifesciences stock?
IART stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Jennison Associates LLC, Millennium Management LLC, Falcon Point Capital LLC, Bank of America Corp DE, Martingale Asset Management L P, Dimensional Fund Advisors LP and Bank of New York Mellon Corp. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Glenn Coleman, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Richard E Caruso and Stuart Essig. View Insider Buying and Selling for Integra Lifesciences.
Which institutional investors are buying Integra Lifesciences stock?
IART stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Brown Advisory Inc., Vaughan Nelson Investment Management L.P., BlackRock Inc., First Trust Advisors LP, Massachusetts Financial Services Co. MA, Gotham Asset Management LLC and Atlanta Capital Management Co. L L C. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Donald E Morel Jr. View Insider Buying and Selling for Integra Lifesciences.
How do I buy shares of Integra Lifesciences?
Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Integra Lifesciences' stock price today?
One share of IART stock can currently be purchased for approximately $51.06.
How big of a company is Integra Lifesciences?
Integra Lifesciences has a market capitalization of $4.35 billion and generates $1.19 billion in revenue each year. The life sciences company earns $64.74 million in net income (profit) each year or $1.94 on an earnings per share basis. Integra Lifesciences employs 4,400 workers across the globe.
What is Integra Lifesciences' official website?
How can I contact Integra Lifesciences?
Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected]
MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)
MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days.
